Clinical Trial

Triamcinolone Acetonide Injection for Upper Eyelid Retraction in Thyroid Eye Disease

Study acronym: TREAT-OT
Completed
View on ClinicalTrials.gov →
Summary
Thyroid eye disease frequently causes upper eyelid retraction, which can lead to ocular surface complications and cosmetic concerns. Several medical and surgical treatments have been proposed; however, minimally invasive therapies remain of interest. This study evaluates the efficacy of local triamcinolone acetonide injection administered through transconjunctival and transseptal routes for the treatment of upper eyelid retraction in patients with inactive thyroid eye disease. Patients with thyroid eye disease and upper eyelid retraction were treated with a combined subconjunctival and transcutaneous injection of triamcinolone acetonide. Clinical measurements including margin reflex distance 1 (MRD1), palpebral fissure height, visual acuity, intraocular pressure, and Clinical Activity Score (CAS) were evaluated before treatment and one month after intervention.
Trial Details
NCT Number NCT07471997
Lead Sponsor Instituto de Oftalmología Fundación Conde de Valenciana
Conditions Thyroid Eye Disease, TED
Enrollment 15 participants
Start Date 2024-06-20
Primary Completion 2025-02-20 (estimated)
Study Completion 2025-02-20 (estimated)
Updated on ClinicalTrials.gov 2026-03-16